Jeremy Cohen1, Carel J Pretorius, Jacobus P J Ungerer, John Cardinal, Antje Blumenthal, Jeff Presneill, Marcela Gatica-Andrades, Paul Jarrett, Melissa Lassig-Smith, Janine Stuart, Rachel Dunlop, Therese Starr, Bala Venkatesh. 1. 1Burns Trauma and Critical Care Research Centre, University of Queensland, Royal Brisbane Hospital, Brisbane, QL, Australia. 2Pathology Queensland Department of Chemical Pathology, University of Queensland, Brisbane, QL, Australia. 3Department of Chemical Pathology, Pathology Queensland, Queensland Health, Brisbane, QL, Australia. 4The University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Brisbane, QL, Australia. 5Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, QL, Australia. 6Department of Intensive Care, Princess Alexandra and Wesley Hospitals, University of Queensland, Brisbane, QL, Australia.
Abstract
OBJECTIVES: To measure tissue glucocorticoid sensitivity in patients with septic shock and determine its relationship to standard measurements of adrenal function and of outcome. DESIGN: Prospective observational trial. SETTING: Teaching hospital ICU. SUBJECTS: Forty-one patients and 20 controls were studied. INTERVENTIONS: Glucocorticoid sensitivity was measured by in vitro suppression of cytokine production from lipopolysaccharide-stimulated leukocytes. MEASUREMENTS AND MAIN RESULTS: There was no significant difference between the groups in the relative suppression of cytokine production, although there was a greater range and variance in the patient data. Patients in the lowest quartile of glucocorticoid sensitivity had higher Acute Physiology and Chronic Health Evaluation II scores (25 [24-28] vs 20 [14-23]; p = 0.02) and a trend toward higher mortality (30% vs 0%; p = 0.2) compared to those in the highest. The mRNA expression of the β variant of the glucocorticoid receptor and the 11-β hydroxysteroid dehydrogenase 2 isozyme were significantly higher in patients compared to controls (8.6-fold, p = 0.002 and 10.1-fold, p = 0.0002, respectively). Changes in mRNA expression of these genes did not correlate with measurements of glucocorticoid sensitivity. CONCLUSIONS: Patients with septic shock and controls do not differ in their median glucocorticoid sensitivity. However, patients exhibited a greater variability in glucocorticoid responsiveness and had evidence of association between increased sickness sensitivity and reduced glucocorticoid sensitivity. Sensitivity to glucocorticoids did not appear to be mediated by changes in the expression of the β variant of the glucocorticoid receptor or the 11-β hydroxysteroid dehydrogenase 2 isozyme.
OBJECTIVES: To measure tissue glucocorticoid sensitivity in patients with septic shock and determine its relationship to standard measurements of adrenal function and of outcome. DESIGN: Prospective observational trial. SETTING: Teaching hospital ICU. SUBJECTS: Forty-one patients and 20 controls were studied. INTERVENTIONS: Glucocorticoid sensitivity was measured by in vitro suppression of cytokine production from lipopolysaccharide-stimulated leukocytes. MEASUREMENTS AND MAIN RESULTS: There was no significant difference between the groups in the relative suppression of cytokine production, although there was a greater range and variance in the patient data. Patients in the lowest quartile of glucocorticoid sensitivity had higher Acute Physiology and Chronic Health Evaluation II scores (25 [24-28] vs 20 [14-23]; p = 0.02) and a trend toward higher mortality (30% vs 0%; p = 0.2) compared to those in the highest. The mRNA expression of the β variant of the glucocorticoid receptor and the 11-β hydroxysteroid dehydrogenase 2 isozyme were significantly higher in patients compared to controls (8.6-fold, p = 0.002 and 10.1-fold, p = 0.0002, respectively). Changes in mRNA expression of these genes did not correlate with measurements of glucocorticoid sensitivity. CONCLUSIONS:Patients with septic shock and controls do not differ in their median glucocorticoid sensitivity. However, patients exhibited a greater variability in glucocorticoid responsiveness and had evidence of association between increased sickness sensitivity and reduced glucocorticoid sensitivity. Sensitivity to glucocorticoids did not appear to be mediated by changes in the expression of the β variant of the glucocorticoid receptor or the 11-β hydroxysteroid dehydrogenase 2 isozyme.
Authors: Djillali Annane; Stephen M Pastores; Wiebke Arlt; Robert A Balk; Albertus Beishuizen; Josef Briegel; Joseph Carcillo; Mirjam Christ-Crain; Mark S Cooper; Paul E Marik; Gianfranco Umberto Meduri; Keith M Olsen; Bram Rochwerg; Sophia C Rodgers; James A Russell; Greet Van den Berghe Journal: Intensive Care Med Date: 2017-09-21 Impact factor: 17.440
Authors: Marcela Gatica-Andrades; Dimitrios Vagenas; Jessica Kling; Tam T K Nguyen; Helen Benham; Ranjeny Thomas; Heinrich Körner; Bala Venkatesh; Jeremy Cohen; Antje Blumenthal Journal: Blood Adv Date: 2017-07-10
Authors: Anders Perner; Andrew Rhodes; Bala Venkatesh; Derek C Angus; Ignacio Martin-Loeches; Jean-Charles Preiser; Jean-Louis Vincent; John Marshall; Konrad Reinhart; Michael Joannidis; Steven M Opal Journal: Intensive Care Med Date: 2017-01-27 Impact factor: 17.440
Authors: Karolina A Zielińska; Laura Van Moortel; Ghislain Opdenakker; Karolien De Bosscher; Philippe E Van den Steen Journal: Front Immunol Date: 2016-12-14 Impact factor: 7.561
Authors: Miguel A Ibarra-Estrada; Quetzalcóatl Chávez-Peña; Claudia I Reynoso-Estrella; Jorge Rios-Zermeño; Pável E Aguilera-González; Miguel A García-Soto; Guadalupe Aguirre-Avalos Journal: World J Crit Care Med Date: 2017-02-04